Carcinoembryonic antigen as prognostic factor for metastatic non-small cell lung cancer by percutaneous cryosurgery.
Carcinoembryonic antigen (CEA) is a prognostic marker for early-stage non-small cell lung cancer (NSCLC), and cryoablation is a new therapeutic alternative for lung cancer. We determined whether cryoablation-induced changes in serum CEA levels correlated with tumor type (adenocarcinoma or squamous carcinoma) and treatment type (comprehensive therapy [cryoablation of all intra- and extrapulmonary tumors] or palliative therapy [cryoablation of only extrapulmonary tumors]) in patients with metastatic NSCLC, and assessed whether pre-treatment CEA levels predicted overall survival (OS). We retrospectively reviewed the clinical data of 88 patients with metastatic NSCLC who underwent comprehensive (62 patients) or palliative (26 patients) therapy. Pre- and post-cryoablation serum CEA levels and overall survival were determined for all patients. Cryoablation significantly reduced CEA levels in adenocarcinoma, but not squamous carcinoma, patients. Among adenocarcinoma patients, the cryoablation-induced reduction in CEA levels was significantly greater after comprehensive treatment than after palliative treatment; the OS of patients under comprehensive cryoablation was longer than those under palliative treatment. Among adenocarcinoma patients receiving comprehensive cryoablation, OS was significantly longer in those with normal pre-treatment serum CEA levels than in those with abnormal pre-treatment serum CEA levels. Pretreatment level and change of serum CEA can be a good indicator for therapeutic effects and OS in metastatic NSCLC patients under percutaneous cryosurgery.
Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou, Guangdong, China Fuda Institute of Cryosurgery for Cancer, Guangzhou, Guangdong, China.
Haibo
H
Li
Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou, Guangdong, China.
Kui
K
Tang
Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou, Guangdong, China Fuda Institute of Lung Cancer, Guangzhou, Guangdong, China.
Lizhi
L
Niu
Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou, Guangdong, China.
Yingqing
Y
Liang
Fuda Institute of Lung Cancer, Guangzhou, Guangdong, China Fuda Institute of Cryosurgery for Cancer, Guangzhou, Guangdong, China.
Jialiang
J
Li
Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou, Guangdong, China Fuda Institute of Lung Cancer, Guangzhou, Guangdong, China.
Jibing
J
Chen
Fuda Cancer Hospital, Jinan University School of Medicine, Guangzhou, Guangdong, China Fuda Institute of Lung Cancer, Guangzhou, Guangdong, China.
Kecheng
K
Xu
D000230:Adenocarcinoma / Q000097:blood* / Q000401:mortality / Q000556:secondary / Q000601:surgery; D002272:Carcinoembryonic Antigen / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000401:mortality / Q000556:secondary / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000401:mortality / Q000556:secondary / Q000601:surgery; D003452:Cryosurgery; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D025321:Surgery, Computer-Assisted; D016019:Survival Analysis; D016896:Treatment Outcome
D002272:Carcinoembryonic Antigen
Cryosurgery; carcinoembryonic antigen; metastatic non-small cell lung cancer